MAR 18, 2015 9:57 PM PDT

Immunotherapy: New Hope for Patients With Advanced Lung Cancer

WRITTEN BY: Ilene Schneider
In the late 1800s, a New York surgeon named William Coley noticed that some patients with cancer seemed to fare better if they developed an infection after undergoing surgery. Suspecting that the immune system played a role in this mysterious response, he tried treating cancer patients with bacteria in an effort to turn on the immune system. Coley's bold experiments largely failed, however, and faded into obscurity as other cancer treatments, such as radiation and chemotherapy, were put into practice.

Coley wasn't wrong-just far ahead of his time. More than a century later, advances in how the immune system can be harnessed to fight cancer have offered new hope to patients with lung cancer. One of the latest immunotherapies to reach the market is a drug called nivolumab (Opdivo), which the FDA recently approved for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC).

"‘Groundbreaking' and ‘revolutionary'" often overstate the case, but they truly apply to the impact of the new immunotherapy agents that target the PD-1 pathway for NSCLC," said Naiyer A. Rizvi, MD, of the Herbert Irving Comprehensive Cancer Center and director of thoracic oncology and immunotherapeutics in the Department of Medicine at NewYork-Presbyterian Hospital/Columbia University Medical Center.

Nivolumab restores the immune system's delicate balance by disabling the PD-1 protein on T cells. PD-1 works by suppressing T cell activity, so when this "checkpoint" protein is inhibited, T cells can go about their business.

Dr. Rizvi led a lung cancer trial recently published in Lancet Oncology that was key to approval of nivolumab for squamous lung cancer. "When I first started treating patients with nivolumab in 2008, it was hard to imagine how dramatically this could help patients who were resistant to all of our standard treatments," said Dr. Rizvi. "We have some patients who are still alive many years after taking this drug, with no evidence of cancer. This has never been seen with standard lung cancer treatment."

While some patients with NSCLC respond well to PD-1 inhibitors, others do not. Dr. Rizvi and his colleagues (at Memorial Sloan Kettering Cancer Center) thought that the cancers that had accumulated the most DNA damage were more likely to have worn out the immune system and would likely be helped the most by PD-1 inhibitors.

They tested this by sequencing tumor DNA from both responders and non-responders to treatment with pembrolizumab (Keytruda), a PD-1 inhibitor. Among their findings, published in March in Science, was that patients with a great deal of DNA damage were far more responsive to treatment than those with less DNA damage. "We were able to use advances in sequencing technology to study the entire exome-the protein-coding genes of the genome-of tumors from patients with NSCLC who were treated with pembrolizumab. We found that the more genetically damaged the tumor was, the more likely the patient was to respond to PD-1 inhibitors."

"This is an important first step toward being able to predict who will respond to PD-1 inhibitors and could be a new way to think about precision medicine based on the sequencing of tumor DNA," said Dr. Rizvi. "This collaboration among clinical researchers, geneticists, and immunologists shows how a team of scientists can work together to help patients fight cancer."

Source: Columbia University
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 16, 2021
Cell & Molecular Biology
A Potential Way to Prevent Metastatic Cancer
JUN 16, 2021
A Potential Way to Prevent Metastatic Cancer
Metastatic cancer is the deadliest, and it can happen years after cancer has been treated to the point of remission. Met ...
JUL 22, 2021
Cell & Molecular Biology
Cancer Cells in the Lab Aren't Like Cancer Cells in the Body
JUL 22, 2021
Cancer Cells in the Lab Aren't Like Cancer Cells in the Body
To study biology, researchers need models. Once those models might have been a bit limited to organisms like rats or mic ...
AUG 26, 2021
Cancer
COVID-19 Vaccination Induces Strong Immunity in Cancer Patients
AUG 26, 2021
COVID-19 Vaccination Induces Strong Immunity in Cancer Patients
Cancer patients have a higher risk of developing severe symptoms from a COVID-19 infection.   Many cancer pati ...
OCT 04, 2021
Cancer
Predicting Progression-Free Survival in a Melanoma Study
OCT 04, 2021
Predicting Progression-Free Survival in a Melanoma Study
IsoPlexis’ Single-Cell Proteomics Predict Progression-Free Survival in Melanoma Study While advancements in oncolo ...
SEP 23, 2021
Immunology
Enhanced Hamster Cells as Super Drug Factories
SEP 23, 2021
Enhanced Hamster Cells as Super Drug Factories
Antibodies are highly specialized proteins produced by the immune system that stick on to foreign invaders in the body w ...
OCT 14, 2021
Clinical & Molecular DX
Weighing Cancer Cells Helps Predict Treatment Outcomes
OCT 14, 2021
Weighing Cancer Cells Helps Predict Treatment Outcomes
Not all cancer patients respond to oncology treatments in the same way. Some might show signs of improvement as the ther ...
Loading Comments...